Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822751 | 0.88 | TRPM5 (0.36) | RAB9ANPC1SMN1; SMN2ATMNPY5R | |
| SCHEMBL3633708 | 0.78 | NPC1 (0.39) | RAB9ANPC1SMN1; SMN2ATMNPY5R | |
| SCHEMBL1822725 | 0.77 | NOTUM (0.38) | RAB9ANPC1SMN1; SMN2GRM2MAPT | |
| SCHEMBL1823938 | 0.77 | SLC6A2 (0.41) | RAB9ANPC1SMN1; SMN2ATMDRD2 | |
| SCHEMBL1823936 | 0.77 | USP30 (0.42) | SCD5 | |
| SCHEMBL19995557 | 0.74 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2ATMNPY5R | |
| SCHEMBL19995535 | 0.74 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2ATMNPY5R | |
| SCHEMBL19995521 | 0.74 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2ATMNPY5R | |
| SCHEMBL1820929 | 0.73 | SLC6A2 (0.42) | MAPT | |
| SCHEMBL1822924 | 0.73 | SLC6A2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197760-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-08-05 | — | — | US | disclosed |
| EP-2155669-A1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148799-A1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197760-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | SLC6A2, SLC6A3, SLC18A2 | RAB9A 1288/4885NPC1 1701/4885SMN1; SMN2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.